David Hoang
Stock Analyst at Deutsche Bank
(3.83)
# 868
Out of 5,182 analysts
50
Total ratings
50%
Success rate
11.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Buy | $55 → $88 | $73.01 | +20.53% | 2 | Apr 14, 2026 | |
| ATAI AtaiBeckley | Initiates: Buy | $12 | $4.03 | +197.77% | 1 | Mar 27, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $56 → $90 | $59.70 | +50.75% | 4 | Mar 10, 2026 | |
| APGE Apogee Therapeutics | Initiates: Buy | $103 | $92.20 | +11.71% | 1 | Dec 10, 2025 | |
| ALKS Alkermes | Maintains: Buy | $55 → $45 | $34.53 | +30.32% | 3 | Nov 13, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $65 → $280 | $342.50 | -18.25% | 2 | Oct 17, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $54 → $36 | $29.99 | +20.04% | 4 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Sell | $6 → $12 | $21.55 | -44.32% | 10 | Aug 15, 2025 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $20 → $35 | $22.17 | +57.87% | 5 | May 21, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $20.57 | +50.70% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $10.98 | +491.99% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $176 | $188.99 | -6.87% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $133.25 | +18.57% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $2.82 | +148.23% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $8.63 | +85.40% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.13 | +287.41% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $309.66 | -28.95% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $69.51 | +15.09% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $0.45 | +572.65% | 1 | Dec 7, 2022 |
Spyre Therapeutics
Apr 14, 2026
Maintains: Buy
Price Target: $55 → $88
Current: $73.01
Upside: +20.53%
AtaiBeckley
Mar 27, 2026
Initiates: Buy
Price Target: $12
Current: $4.03
Upside: +197.77%
Xenon Pharmaceuticals
Mar 10, 2026
Maintains: Buy
Price Target: $56 → $90
Current: $59.70
Upside: +50.75%
Apogee Therapeutics
Dec 10, 2025
Initiates: Buy
Price Target: $103
Current: $92.20
Upside: +11.71%
Alkermes
Nov 13, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $34.53
Upside: +30.32%
Praxis Precision Medicines
Oct 17, 2025
Maintains: Buy
Price Target: $65 → $280
Current: $342.50
Upside: -18.25%
Harmony Biosciences Holdings
Sep 25, 2025
Maintains: Buy
Price Target: $54 → $36
Current: $29.99
Upside: +20.04%
Sarepta Therapeutics
Aug 15, 2025
Maintains: Sell
Price Target: $6 → $12
Current: $21.55
Upside: -44.32%
ACADIA Pharmaceuticals
May 21, 2025
Upgrades: Buy
Price Target: $20 → $35
Current: $22.17
Upside: +57.87%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $20.57
Upside: +50.70%
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $10.98
Upside: +491.99%
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $188.99
Upside: -6.87%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $133.25
Upside: +18.57%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $2.82
Upside: +148.23%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $8.63
Upside: +85.40%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $4.13
Upside: +287.41%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $309.66
Upside: -28.95%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $69.51
Upside: +15.09%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $0.45
Upside: +572.65%